Live
- Gentle in manner, resolute in convictions: Sonia Gandhi pens emotional note for Dr. Manmohan Singh
- 2024: A landmark year for India's defence achievements and breakthroughs
- 2025 Horoscopes: Insights and Guidance by Pt. Umesh Chandra Pant
- Osamu Suzuki was a legendary figure in global auto industry: PM Modi
- “AMOEBA”: Celebrating the Journey of Telugu Entrepreneur Sri Motaparti Siva Rama Vara Prasad
- Sachin Khedekar recites a poem from director Feroz Abbas Khan’s powerful new play, ‘Hind 1957’
- NABL-QCI appoints Dr. Sandip Shah as chairperson
- Centre transfers Rs 2.23 lakh crore for 1,206 schemes under Direct Benefit Transfer
- BGT 2024-25: Watching Konstas bat reminds me of Symonds, says Hayden
- 75 iconic lighthouses in India saw more than 10 lakh visitors till September
Glenmark gets USFDA nod to market generic drug
Glenmark Pharmaceuticals on Thursday said it has received approval from the US health regulator to market a medication used to treat and prevent seizures.
New Delhi: Glenmark Pharmaceuticals on Thursday said it has received approval from the US health regulator to market a medication used to treat and prevent seizures.
The company has received approval from the US Food and Drug Administration (USFDA) for Topiramate Capsules USP in 15 mg and 25 mg strengths, the Mumbai-based drug maker said in a statement. The company's product is therapeutically equivalent to Janssen Pharmaceuticals Inc's Topamax Capsules (15 mg and 25 mg), it added.
Glenmark said the drug will be distributed in the US market by Glenmark Pharmaceuticals Inc, USA. According to IQVIA sales data for the 12-month period ending May 2024, the Topamax capsules (15 mg and 25 mg) achieved annual sales of around USD 21.9 million. Glenmark's current portfolio consists of 198 products authorised for distribution in the US marketplace. The company said 50 abbreviated new drug applications (ANDAs) are currently pending for approval with the USFDA. Shares of Glenmark Pharmaceuticals were trading 0.88 per cent up at Rs 1,422.85 apiece on the BSE.
